Mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, has shown efficacy in ulcerative colitis and was approved by the US Food and Drug Administration (FDA ...
Eli Lilly has the results it was looking for in a second, confirmatory trial of its anti-IL-23p19 antibody mirikizumab in ulcerative colitis as it waits for the outcome of regulatory reviews in ...
The FDA has issued a complete response letter to Eli Lilly, turning down its attempt to get approval for anti-IL-23p19 antibody mirikizumab as a treatment for ulcerative colitis (UC). The company ...
Patients received mirikizumab 900mg by intravenous (IV) infusion at Week 0, Week 4 and Week 8 followed by a maintenance dose of 300mg by subcutaneous injection (SC) at Week 12 and then every 4 ...
Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. 2,3 "Many ...
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh ...
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...
1 About Omvoh®Omvoh® (mirikizumab-mkrz) is an interleukin-23p19 antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results